Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
A phase 2 non-randomized study to assess the safety and efficacy of the combination of
tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in
HER2-neu positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
Georgetown University Indiana University Johns Hopkins University Seagen Inc. Seattle Genetics, Inc. Translational Breast Cancer Research Consortium University of California, San Francisco University of Chicago University of Michigan University of Texas University of Washington